643 completed, 311 active not recruiting, 248 recruiting, 240 terminated. 1071 Phase 2, 653 Phase 1, 172 Phase 3, 31 Early Phase 1, 18 Not applicable.
Follow Nivolumab: new trials by email Literature Review of Nivolumab trials Research Report on Nivolumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers BI 1831169, nivolumab - Solid Tumors | Phase 1 | Suspended | Boehringer Ingelheim | 46 | 2027-08-03 | 2026-07-07 |
| The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. Nivolumab & Ipilimumab, Nivolumab + Ipilimumab - Advanced Kidney Cancer | Phase 3 | Not yet recruiting | Guliz Ozgun | 142 | 2027-02-01 | 2026-10-01 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Neoadjuvant RP2 + Nivolumab in Patients With Melanoma RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection - MelanomaCutaneous Melanoma Resectable, Melanoma | Phase 2 | Not yet recruiting | Yana Najjar | 34 | 2026-12-31 | 2026-10-07 |
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. Nivolumab, Gemcitabine, Cisplatin - Advanced Biliary Tract Cancer(BTC) | Phase 2 | Withdrawn | National Health Research Institutes, Taiwan | 2026-12-01 | 2026-07-02 | |
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Opdualag, Nivolumab - Cutaneous Melanoma, Melanoma Stage IV | Phase 2 | Recruiting | University Health Network, Toronto | 54 | 2026-11-30 | 2026-10-13 |
| Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma Axelopran, Nivolumab - Unresectable Cutaneous Melanoma | Phase 1 / Phase 2 | Recruiting | John Kirkwood | 28 | 2026-11-30 | 2026-10-19 |
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Nivolumab + Relatlimab - Unresectable Melanoma, Metastatic Melanoma | Phase 4 | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-11-15 | 2026-08-12 |
| Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older Anakinra, Biospecimen Collection, Computed Tomography - Melanoma | Phase 1 | Not yet recruiting | University of Southern California | 40 | 2026-11-01 | 2026-09-24 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) Divarasib, Pembrolizumab, Nivolumab - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Hoffmann-La Roche | 400 | 2026-10-06 | 2026-10-13 |
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-10-01 | 2026-09-29 |
| A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab - Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 27 | 2026-10-01 | 2026-10-05 |
| Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma Ipilimumab, Nivolumab - Melanoma | Phase 2 | Withdrawn | University of Utah | 2026-10-01 | 2026-10-19 |
Showing 20 of 1715. Sign in to see all of them.
Melanoma (278) · Carcinoma, Non-Small-Cell Lung (248) · Carcinoma, Renal Cell (145) · Neoplasms (101) · Neoplasm Metastasis (100) · Carcinoma, Hepatocellular (90) · Squamous Cell Carcinoma of Head and Neck (88) · Colorectal Neoplasms (82) · Lung Neoplasms (77) · Stomach Neoplasms (64) · Pancreatic Neoplasms (56) · Carcinoma, Transitional Cell (51) · Hodgkin Disease (47) · Head and Neck Neoplasms (43) · Urinary Bladder Neoplasms (43)
Bristol-Myers Squibb (229) · National Cancer Institute (NCI) (95) · M.D. Anderson Cancer Center (66) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (40) · Memorial Sloan Kettering Cancer Center (33) · H. Lee Moffitt Cancer Center and Research Institute (31) · Ono Pharmaceutical Co., Ltd. (26) · Dana-Farber Cancer Institute (23) · The Netherlands Cancer Institute (21) · Emory University (17) · Washington University School of Medicine (16) · City of Hope Medical Center (14) · Mayo Clinic (12) · NYU Langone Health (12) · Massachusetts General Hospital (11)
United States (1131) · France (252) · Spain (239) · Italy (209) · Canada (204) · Australia (187) · Germany (177) · United Kingdom (166) · Netherlands (132) · Belgium (125) · Japan (122) · Poland (112) · South Korea (104) · China (94) · Brazil (84)
Project Leader (16) · Mitsunobu Tanimoto (5) · Ahmad Tarhini, MD, PhD (4) · Alex F Herrera (4) · Dung Le, MD (4) · Eric Jonasch, MD (4)
PMID 36648215, PMID 39504507, PMID 30215677, PMID 32691060, PMID 31401903, PMID 33058158, PMID 35383907, PMID 36897427, PMID 37505794, PMID 39462179, PMID 39777725, PMID 40341124, PMID 42836590, PMID 21917625, PMID 22658127, PMID 23724867, PMID 27718784, PMID 28662232, PMID 29023213, PMID 29158363, PMID 29408986, PMID 29489427, PMID 29982279, PMID 31112476, PMID 31992108, PMID 32198149, PMID 32303612, PMID 32352505, PMID 32557715, PMID 32852531, PMID 32961119, PMID 33001135, PMID 33062947, PMID 33277223, PMID 33362722, PMID 33394722, PMID 33449799, PMID 33526329, PMID 33558721, PMID 33735809, PMID 34272087, PMID 34385708, PMID 34503735, PMID 34855329, PMID 34937871, PMID 35031545, PMID 35304832, PMID 35383114, PMID 35622074, PMID 35623069
2016 (43), 2017 (43), 2018 (42), 2015 (23), 2023 (22), U10CA180820 (18), 2025 (16), U10CA180821 (16), 2014 (14), 2019 (13), P30CA138292 (12), P30CA033572 (11), P30CA060553 (11), U10CA180888 (11), U10CA180868 (10)